As YAP/TAZ directly upregulate PD-L1 in cancer cells, PD-1/PD-L1 checkpoint inhibitors, standard therapies for various types of cancer, could be effective against cancers with YAP/TAZ activation. The gene discussed is CD274; the disease is cancer.